The Pharmacy Quality Alliance created a guide that highlights services that improve food and nutrition security, along wtih other SDOH, for patients to improve medication outcomes. What else does the guide discuss? Click here to learn more. bit.ly/47KBtEQ

Pharmacy Times learned that pharmacists had significant levels of burnout last year. Let us know how you feel this year and take our 10 minute 2024 Burnout and Mental Health Survey. bit.ly/3HWwfvD

Pharmacists are a significant resource for patients with HIV. But how are they transforming patient care? Find out here. bit.ly/3SfB2g9

Burnt out? Tell us about it! Please take our 10-minute 2024 Burnout and Mental Health Survey. Pharmacy Times will review the results and report on how they can impact the future of pharmacy. bit.ly/3HWwfvD

A new technology can predict a person's risk of developing Alzheimer dementia. Click the link to learn about this screening tool. bit.ly/3SfB2g9

Pharmacists can optimize the treatment of HIV when they understand medication history, drug/drug interactions, educate patients, and improve access to lifesaving medication. Learn more here. bit.ly/3SfB2g9

Burnout can shape the trajectory of the pharmacy industry. Please take a minute to fill out Pharmacy Time's 2024 burnout survey- let other pharmacist's know where you stand, and let your voice be heard.

The FDA accepted a biologics license application for priority review for afamitresgene autoleucel (afami-cel; Adaptimmune Therapeutics plc) for the treatment of advanced synovial sarcoma, according to a recent press release. Read more here. bit.ly/3HOEPMA

It is important that pharmacists and pharmacy professionals stay informed about new treatments for gut dysbiosis to help patients seeking treatment, according to Sharon Rimon, NP. Read more here.bit.ly/3uvXB8t

Did you take the 2024 Burnout and Mental Health Survey?! We'll be producing articles that discuss your results and how they could impact the future of pharmacy. bit.ly/3HWwfvD

The FDA accepted an application for afamitresgene autoleucel for the treatment of advanced synovial sarcoma, which increased median overall survival to approximately 17 months. bit.ly/3HOEPMA

The Biden-Harris Administration said that its new Cell and Gene Therapy Access Model will lower the cost for gene therapy for the treatment of sickle cell disease. Read more here. bit.ly/42xQUQ5

Celltrion USA submitted a biologics license application for a tocilizumab biosimilar, which is indicated for the treatment of arthritis and cytokine release syndrome. Learn more here. bit.ly/4bAsKbv

Happy Valentine's Day from Pharmacy Times! Shane #pharmacy

Biogen will advance its research on lecanemab-irmb, BIIB080, and BIIB113 for the treatment of Alzheimer disease. However, they will discontinue the development and commercialization of aducanumab. Click the link to learn why. bit.ly/3OB1Nun

A new CMS model aims to lower the cost of, and improve accessibility to gene therapies for sickle cell disease. This shortly follows the approval of 2 cell-based gene therapy treatments in December 2023. Click the link to learn more. bit.ly/42xQUQ5

The FDA approved an sBLA for teclistamab-cqyv (Tecvayli; Janssen Biotech, Inc.) for the treatment of patients with relapsed or refractory multiple myeloma. Head to the PT website to learn more. bit.ly/48q3Ush #pharmacy #multiple myeloma

The FDA may delay the approval of donanemab for the treatment of Alzheimer disease. Click the link to learn more and follow Pharmacy Times for continued updates. bit.ly/3Trxolb

Did you know that multiple myeloma is the second most common blood cancer? Click the link to learn how to raise awareness for this disease this March: bit.ly/4cgWzhC

The FDA approved biosimilars denosumab-bbdz (Wyost; Sandoz) and denosumab-bbdz (Jubbonti; Sandoz) for bone-related conditions. Click the link to learn how these can impact at-risk patients. bit.ly/3wLiTzH